Frontal sinus cancer resection and reconstruction

Mannu, Gurdeep; Iyer, N. Gopalakrishna; Shah, Jatin P.

doi:10.1258/shorts.2010.010096

Cited by 7 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anatomy of the region, with the proximity of several important structures, adds further complexity to treatment planning. Although both surgical and radiotherapy approaches have advanced in recent years, with endoscopic resections and intensity‐modulated radiotherapy, we did not see this translate into an improvement in OS over the time period assessed in MVA in the current study. It is likely that we did not observe an improvement in survival over time in the current study because many of these advancements predate our study period.…”

Section: Discussioncontrasting

confidence: 72%

A comprehensive comparative analysis of treatment modalities for sinonasal malignancies

Robin

Jones

Gordon

et al. 2017

Cancer

139

170

View full text Add to dashboard Cite

BACKGROUND: Sinonasal malignancies are a rare and heterogeneous group of tumors for which there is a paucity of robust data with which to guide management decisions. The authors used the National Cancer Data Base to better understand the presenting characteristics of these tumors and to compare outcomes by treatment modality. METHODS: The National Cancer Data Base was queried for sinonasal malignancies diagnosed between 2004 and 2012. Overall survival was assessed using multivariate analyses and propensity score matching. RESULTS: A total of 11,160 patients were identified for the initial analysis. The majority were male, aged 40 to 69 years, with tumors of the nasal cavity or maxillary sinus. Squamous cell histology was most common. The majority of patients presented with advanced tumor stage but without locoregional lymph node or distant metastases. Treatment modalities were compared for squamous cell carcinomas. In multivariate analysis, compared with surgery alone, patients who received adjuvant radiotherapy (hazard ratio [HR], 0.658 [P<.001]), adjuvant chemoradiotherapy (HR, 0.696 [P=.002]), or neoadjuvant therapy (HR, 0.656 [P = .007]) had improved overall survival. Patients who received radiotherapy alone (HR, 1.294 [P=.001]) or chemotherapy alone (HR, 1.834 [P<.001]) had worse outcomes. These findings were validated in propensity score matching. It is important to note that neoadjuvant chemoradiotherapy was associated with achieving a negative surgical margin (odds ratio, 2.641 [P=.045]). CONCLUSIONS: Surgery is the mainstay of therapy for patients with sinonasal malignancies, but multimodality therapy is associated with improved overall survival.

show abstract

Section: Discussioncontrasting

confidence: 72%

A comprehensive comparative analysis of treatment modalities for sinonasal malignancies

Robin

Jones

Gordon

et al. 2017

Cancer

139

170

View full text Add to dashboard Cite

show abstract

“…Malignant tumors of the frontal sinus are very rare and mainly documented as case reports in literature (16). In our study, frontal sinus malignancy was found only in one case.…”

Section: Discussionmentioning

confidence: 99%

“…Our results are in good agreement with the previous studies where the most frequent primary site of tumors was maxillary sinus (87%) followed by ethmoid sinus (56%) ( 12 , 13 ). Malignant tumors of the frontal sinus are very rare and mainly documented as case reports in literature ( 16 ). In our study, frontal sinus malignancy was found only in one case.…”

Section: Discussionmentioning

confidence: 99%

Paranasal sinuses malignancies: A 12-year review of clinical characteristics

Danesh-Sani

Sarafraz²,

Chamani³

et al. 2016

Med Oral

View full text Add to dashboard Cite

BackgroundInadequate epidemiologic investigations of the paranasal sinuses malignancies prompted this retrospective study with special emphasis on a major group of 111 tumors.Material and MethodsClinical records of 111 patients with histologically confirmed malignant tumors of the paranasal sinuses were investigated retrospectively from April 2000 to January 2012. Collection of data included demographic information, clinical manifestations, treatment plans, and histopathology of the tumor.ResultsThere were 69 (62.16%) male and 42 (37.83%) female patients (male-to-female ratio of 1.6:1), with a median age of 49±12.2 years (range 21 to 88 years). A high level of occurrence was noticed in the fifth (26.3%) decade of life. The most frequent histological types were squamous cell carcinoma (43.5%) and adenoid cystic carcinoma (19%). Among clinical manifestations, nasal obstruction was the most frequent followed by diplopia, and facial swelling. Fifty three patients (47.74%) were treated with combined approach of surgery and radiation therapy.ConclusionsParanasal sinuses malignancies are rare conditions with nonspecific symptoms which make early diagnosis of the lesions more challenging. The optimal therapeutic protocol for patients suffering from these tumors is still a somewhat controversial entity and requires further studies. Key words:Paranasal sinuses, malignancy, surgery,radiotherapy.

show abstract

“…Primary frontal sinus squamous cell carcinoma (pFS‐SCC) in human beings was first described in 1907 by Prawssud, 1 and accounts for 0.01–0.03% of all head and neck cancers 2–4 . In human beings, nasal and paranasal cancers tend to present most commonly between 50 and 70 years of age 5 .…”

Section: Introductionmentioning

confidence: 99%

Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib

Vos¹,

Vega

Noorman³

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

In human medicine, primary frontal sinus squamous cell carcinoma (pFS-SCC) is not frequently reported. In veterinary medicine, frontal sinus SCC is exclusively described as an extension of nasal cavity SCC. To our knowledge, this is the first publication concerning canine pFS-SCC, diagnosed using histology or cytology and medical imaging, in three dogs. The tumours extended into the orbit or brain cavity, without nasal involvement. Treatment was initiated with piroxicam-carboplatin. Prolongation of carboplatin delivery with a low dose intensity was performed on dogs with a favourable initial response. Dog 1 achieved a complete remission (CR), but was euthanized 344 days after start of therapy. Dog 2, still alive 3 years after start of therapy and in CR, received 14 carboplatin deliveries. In dog 3, after changing the treatment protocol into piroxicam-toceranib, a significant tumour reduction occurred, but the dog was euthanized after 195 days because of a relapse.

show abstract

Frontal sinus cancer resection and reconstruction

Cited by 7 publications

References 10 publications

A comprehensive comparative analysis of treatment modalities for sinonasal malignancies

A comprehensive comparative analysis of treatment modalities for sinonasal malignancies

Paranasal sinuses malignancies: A 12-year review of clinical characteristics

Primary frontal sinus squamous cell carcinoma in three dogs treated with piroxicam combined with carboplatin or toceranib

Contact Info

Product

Resources

About